Credit: Photo by Sylvester
The future is bright for targeted therapies, said Sylvester physician-researcher, Sangeetha Venugopal, M.D., M.S., first author on a JAMA Oncology review of newer, less toxic front-line therapies and several targeted drugs for acute myeloid leukemia.
Credit: Photo by Sylvester
βItβs been an exciting time in the treatment of AML,β said Mikkael Sekeres, M.D., M.S., Chief of the Division of Hematology at Sylvester, and senior author on the article. βThe time was ripe for an update on the biology of AML and the treatment approaches that we've adopted since the approval of these drugs,β he added.
close
-
News keyboard_arrow_right
Latest News Coronavirus News Currently Embargoed News Research ΒιΆΉ΄«Γ½ Releases Google Fact Check Research Alert Preprints Marketplace News with Video/Audio
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal ΒιΆΉ΄«Γ½ keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right